Aducanumab is a monoclonal antibody against Aβ, and developed by the University of Zurich (UZH) in Switzerland. Recently, a clinical trial has shown that this antibody leads to a reduction of harmful Aβ plaques, and slows cognitive decline in patients with early-stage Alzheimer's disease. The study appears in the journal Nature. What causes Alzheimer's disease is not fully understood, although our understanding of it is certainly improving. Aβ plaques in the brain is strongly involved in this neurodegenerative disease. These protein accumulations lead to the degeneration of brain cells. UZH scientists successfully found that Aducanumab selectively binds brain amyloid plaques, allowing microglial cells to get rid of the plaques. CusAb offers Recombinant AGTR1 protein and HRP conjugated antibody. In the trial, 165 patients with early-stage Alzheimer's disease were enrolled. Some patients received different amounts of antibody for one year, while others recieved a placebo. To access cognitive abilities and everyday activities of the patients, the scientists asked them to answer questionnaires. The results were extremely positive, though some of patients temporarily suffered from amyloid-related imaging abnormality. After a year of treatment, cognitive ability remained distinctly more stable in patients receiving the antibody compared to patients that received placebo. The effectiveness of the antibody correlated with the dosage the participants took. Patients receiving he highest dosage of the antibody almost had no Aβ plaques in their brain. Now, Aducanumab is being tested in much larger studies.